A Phase I Study to Evaluate Two Doses of Wharton’s Jelly-Derived Mesenchymal Stromal Cells for the Treatment of De Novo High-Risk or Steroid-Refractory Acute Graft Versus Host Disease
Rupal P. Soder, Buddhadeb Dawn, Mark L. Weiss, Neil Dunavin, Scott J. Weir, James Mitchell, Meizhang Li, Leyla Shune, Anurag K. Singh, Siddhartha Ganguly, Marc Morrison, Haitham Abdelhakim, Andrew K. Godwin, Sunil Abhyankar, Joseph P. McGuirk
Topics & Concepts
Mesenchymal stem cellWharton's jellyRefractory (planetary science)Graft-versus-host diseaseStem cellMedicineDiseaseBiologyPathologyCell biologyAstrobiologyMesenchymal stem cell researchBone and Joint DiseasesHematopoietic Stem Cell Transplantation